Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Table S1, Figure S1,Table S2, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9 from Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
View through CrossRef
<p>Table S1, Figure S1,Table S2, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9</p>
American Association for Cancer Research (AACR)
Title: Table S1, Figure S1,Table S2, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9 from Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
Description:
<p>Table S1, Figure S1,Table S2, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9</p>.
Related Results
Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
Abstract
Overexpression of HER2 is seen in 15-20% of breast cancer and is a predictor of poor prognosis. Trastuzumab, a monoclonal antibody to the ECD of the HER2 re...
Abstract 1773: Targeting HER2 and Src in HER2-driven ovarian and esophagogastric cancers
Abstract 1773: Targeting HER2 and Src in HER2-driven ovarian and esophagogastric cancers
Abstract
Background: Neratinib, an oral, irreversible pan-HER tyrosine kinase inhibitor, has exhibited clinical activity against HER2-mutant and HER2 over-expressing...
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
Abstract
Aims
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+ APO (HER2...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract
Background While HER2-directed agents are most often used for treating breast cancer, there is increasing evidence that these therapies may be of value in o...
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract
Background: HER2-positive breast cancers comprise 20-30% of all breast cancers; amplification of HER2 confers a poorer prognosis. While treatment with anti-...
Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization
Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization
Abstract
Abstract 2989
Sequential drug combination is a rational approach to maximize tumor killing and minimize side effects in cancer therapy. Howev...
Abstract BL-1: Brinker Award Lecture: How Does HER2 Contribute to Breast Cancer Progression?
Abstract BL-1: Brinker Award Lecture: How Does HER2 Contribute to Breast Cancer Progression?
Abstract
HER2 (also called NEU and ERBB2), a receptor tyrosine kinase frequently overexpressed in breast cancer, is one of the most oncogenic kinases of the human ki...